Presentation of the Centre

The Léon Bérard Centre (CLB) is one of the 18 French Cancer Centers of the Unicancer group. It is a comprehensive cancer Center and a University Hospital involved in screening and care entirely dedicated to cancer, with three overarching aims: care, research and teaching, and the mission to offer the best quality of care to cancer patients. In 2023, the teams of the CLB treated more than 42 000 patients, mainly from the Auvergne Rhône-Alpes region, but also from other areas of France, from French overseas territory and from abroad. The CLB is a reference and innovation center for frequent and rare cancers and has been selected as the coordinating center for the national network of reference centers for sarcomas and rare ovarian cancers.

Main Research Activities

Over 600 full-time researchers are working side-by-side with the medical teams and the patients to facilitate ground-breaking scientific discoveries and their applications in novel treatments.

Core Facilities

Recognized as a cancer referral and treatment facility, the CLB offers a comprehensive range of care by pooling the required skills that grants patients access to the most innovative technics for diagnosis and treatment on a single site.

• 3 state-of-the art operating units
• 8 accelerators (radiotherapy)
• a Department of Clinical Research certified ISO 9001 intregrating early-stage pediatric and adult trials.
• a Translational Research Department with several shared platforms.

Education

As a University Hospital, teaching is one of its principal missions; the CLB is recognized as a Training Institute that offers training in more than twenty areas to health professionals in the field of oncology, every year.

Presentation of the Centre

Leading Cancer Centre in Europe, Gustave Roussy is ranked #4 world's best oncology hospital according to Newsweek magazine  and the first one outside the United States. The institute treats patients with all types of cancer at any age and is expert in the treatment of rare and complex tumours. We place innovation at the heart of a human, scientific and technological revolution in the fight against cancer.  Our physicians and researchers respond to a continuing challenge: deliver patients the fruits of the most recent advances. They devote their energies and their skills to this great challenge: to speed up progress in order to expand the limits of knowledge and offer patients continuing improvements in the specificity of their treatment.

In the Vanguard of Progress

Gustave Roussy brings together the best workers in fundamental, clinical and translational research. Very close collaboration between research scientists and doctors means that patients get access in the shortest possible time to the very latest developments in treatment. Through the impact of its scientific articles and the presence of its researchers at international conferences, Gustave Roussy proves the effectiveness of its model as an integrated centre for research and clinical practice. The activities of the Institute’s research units are concentrated on personalised medicine, immunotherapy, DNA repair and artificial intelligence Our ambition is immense: extending the frontiers of science, continuously reinventing methods of treatment of patients and exploring every source of innovation. And raise the hope of curing cancer in the 21st century.

High technology medicine in the service of mankind

The Institute has expertise in the management of rare cancers and complex tumours. It treats all cancers at every stage of life. It offers its patients individualised care combining innovation and a humane approach. The treatment is important but so is quality of life, physical, psychological and social.

Education

High level training covering the whole fields of cancer therapy. The transmission of knowledge is inseparable from research. L’École des Sciences du Cancer, founded by Gustave Roussy and Paris-Saclay University is a unique training facility in France and employs top-end teaching staff working on training courses covering every aspect of oncology: from basic research to clinical practice.

Presentation of the Centre

The Institut Curie is a foundation of public interest, which combines one of the largest European oncology research center and two state-of-the-art hospitals. Institut Curie, France’s leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group, which treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institute Curie employs 3,800 researchers, physicians, and health professionals across three sites (Paris, Saint-Cloud, and Orsay), all of whom contribute to its three missions of treatment, teaching, and research.

Main Research Activities

In the bylaws of the foundation known as Institut Curie, we propose the development of:

• Basic scientific, translational and clinical research in physics, chemistry, biology and radiobiology
• Diagnostics, follow-up and care given to patients within a hospital group belonging to the Unicancer federation
• Development of research and access to innovation, which requires ties with economic players in order to develop innovations and improve scientific knowledge
• Preservation and transfer of knowledge in the aforementioned areas, in particular through teaching and museology activities.

Education

For Institut Curie, teaching is a function that’s inseparable from research and treatment, and as such is fully part of the foundation's social missions. For the preservation of knowledge, Institute Curie is the keeper of the work conducted by the Curie and Joliot-Curie families, and has a duty to pass on the history of this work to a broad audience. Its contribution to the international influence of research and treatment, in particular in oncology

Presentation of the Centre

The JEAN PERRIN Center, opened in 1973, is a private health institution of public interest, member of the UNICANCER group of the French National Union of Comprehensive Cancer Centers. Certified without restriction by French High Authority of Health in 2003, 2007, 2011 and 2016. By actively participating in bringing together scientific research and medicine in order to develop all forms of medical applications, the Nobel Prize in Physics Jean Perrin lends its name to the will of the continuous progress that drives the teams of our Center of Struggle Against Cancer facing the disease

Main Research Activities

The JEAN PERRIN Center is a regional reference hospital for an innovative and high precision cancer treatment and research and is part of the development of ambulatory surgery in all areas of cancerology. Senology activity with breast diagnosis in 1 day and cryotherapy. The new premises of the radiotherapy allowed the installation of 4 accelerators of high precision. The Clinical Oncology Pharmacy unit has seen its activity gradually increase with the acquisition of a Gallium generator and a new TEP SCAN, linking performance and quality. The Center for Innovation and Research in Nuclear Medicine (CIRMEN) at the Jean Perrin Center aims to become a world reference in the field of radiopharmaceuticals. IMOST, an INSERM-labelled research team dedicated to translational research and radio tracers in oncology, was created in 2017.

Core Facilities

• 4 radiotherapy last generation equipments
• 5 scintillation cameras
• 2 TEP Scan
• 2 scanners
• 110 beds: 41 in medicine; 47 in surgery 15 in intensive care / monitoring 7 radio-protected rooms
• 30 places dedicated to chemotherapy
• 5 places for ambulatory surgery
• 2 places dedicated to the care of emergencies in Oncology
• 6 operating theaters

Education

Positive balance of our scientific production. General improvement of the quality of our publications and increased scientific visibility of the Center. Faithful to its innovative spirit, the Center Jean Perrin, has created create a research and innovation group in cancer control organisations in partnership with the Clermont Research Center of Administration and Management (CRCGM - University of Auvergne).

Presentation of the Centre

Institut Paoli-Calmettes (IPC) is one of the largest university-affiliated cancer centers in France. Its priorities are the diagnosis and treatment of adult cancers, prevention, education, and basic, translational and clinical research.
IPC is involved in the management of more than 10 000 new cases of cancer each year. With 2054 staff-members, including 431 physicians and more than 300 scientists, and an annual budget of ~350 million Euros.

Main research activities

IPC carries out an integrated research program encompassing basic science, translational, clinical and socio-medical research. It hosts two research centers, the Center for Cancer Research of Marseille for biological research, and the Cancer, Biomedicine and Society team for socio medical research. Our main research programs focus on breast cancer, hematologic malignancies and pancreatic cancer.

Core facilities

IPC hosts 17 state-of-the-art technological and clinical platforms including a biobank, a department of clinical research and innovation, a data management center, a data factory, an early phase trial unit, and platforms for preclinical assays, experimental pathology, immunomonitoring, oncogenomics, proteomics, bioinformatics, drug discovery, chemo-biology and cell imaging.

Education

IPC is committed to the education and training. IPC is affiliated to the University of Aix-Marseille and runs 4 Master programs and 4 University diplomas in which 420 students were enrolled in 2023.

Presentation of the Centre

The Montpellier Cancer Institute (ICM, Montpellier, France), created in 1923 by a French authorities’ ordinance and member of the UNICANCER, has four overarching aims: patients' care, research, prevention and teaching. Facing more than 17,000 new cancer cases in the East Occitanie every year, the Institute has developed a medical and scientific strategy, with a national and international visibility, focusing on a personalized and innovative global patient management (medical, psychological and social) from cancer prevention to post-treatment follow-up. Over the years, the ICM rose at the forefront of the top-performing Comprehensive Cancer Centres for clinical, fundamental and translational research in France.

Main Research Activities

Research focused on the patient, spanning from fundamental biology to clinical applications, is a major founding mission of the Institute and its organized in six areas: prevention, fundamental, translational, clinical and methodological research, and human and social sciences. Over 250 researchers are working side-by-side, and with the medical teams, to progress in the fight against cancer. ICM obtained the SIRIC label (Integrated Cancer Research Center) in 2022 for the third time, from the National Cancer Institute (INCa).

Core Facilities

ICM doctors and researchers have access to state-of-the-art core facilities for the benefit of our patients. These include 1 MRIDianLinac, 6 Linear Accelerators, 9 operating rooms, 2 DaVinci surgical robot systems, 1 PET Scan, 2 MRI, 6 technical platforms (1 CyTOF, 1 Protein mass spectrometry …).

Education

Education is strongly rooted in the ICM culture and its medical/paramedical teams are actively involved in university teaching activities as well as in paramedical training courses. In 2016, the ICM has opened the “Montpellier Cancer School” to offer a variety of training opportunities in cancer-related disciplines to health-care providers and scientists.

Description of the Centre and History

The Institute comprises three University hospitals in central-west Paris: European Georges Pompidou, Cochin, and Necker-Enfants Malades. Partnered with Université Paris Cité, they excel in oncology, delivering high-quality cancer care, research, and education. Annually, it treats 8,000 new cancer patients and employ 2,500 staff, including 220 physicians & 350 researchers.

Main Research Activities

The Institute’s research is recognized as a cancer integrated research site (SIRIC CARPEM) by the French National Cancer Institute. Collaborating with 22 research teams from Université Paris Cité and 12 clinical teams, the Institute focuses on identifying biomarkers for precision medicine, integrating “omics” with immunology to tackle 21st-century oncology challenges. In 2023, the Institute published 466 papers in peer-reviewed journals (23% with an IF>10).

Core Facilities

Supported by outstanding hospital facilities (24 operating rooms, surgical robots, PET scans, MRIs), the Institute also offers advanced radiotherapy techniques, including conformal radiotherapy and intensity-modulated radiotherapy. The clinical research is robust, with 198 clinical trials initiated in 2023 and an early phase trials center accredited by the French National Cancer Institute. High-level technical research platforms in genomic, metabolism, proteomic, spatialomic, and AI/bioinformatic are available.

Education

The Institute trains over 240 medical students and 60 PhD candidates in oncology annually, with 115 university professors and lecturers involved in their education. Members have access to more than 100 oncology seminaries each year.

Presentation of the Centre

Created in 1925, the Centre Baclesse in Caen has been carrying out a triple mission in oncology for nearly 100 years: treatment, teaching and research. The Centre Baclesse is a nonprofit private health car establishment of collective interest (ESPIC). As a public hospital service provider, the Centre Baclesse does not operate in the private sector or exceed fees and applies only standard rates. It is recognised as being of public utility and can receive tax-free donations and bequests. The Centre Baclesse is one of only 3 centres in France to offer protontherapy.

Main Research Activities

Sustained activity in both investigation and promotion, with more than 600 patients enrolled at the Centre François Baclesse in category 1 or 2 interventional trials. The clinical research department is labelled by French Health Ministry as Innovation and Research Department (DRCI), labelled by the French National Cancer Institute (INCa) as an early stage cancer clinical trial centre (CLIP²). The most important research programs in the Centre Baclesse include:

• Research in breast and ovarian cancers (organoids)
• New approaches in radiotherapy including preclinical, physical and clinical and quality of life studies focused on stereotactic radiation proton and Hadrontherapy
• Studies of quality of life and survivorships
• Epidemiology with an extensive program of the impact of pesticides
• Oncogenetics
• Artificial Intelligence (AI)

Core Facilities

Medical department:

• 170 beds (99 conventional and 71 day)
• Pharmacy: Personalized medical treatment including chemotherapy, targeted therapy, immunotherapy and supportive cares; Centralised preparation chemotherapy preparation unit. Robotic production of anticancer drugs.

• 50 beds (35 conventional and 15 outpatient)
• 6 operating rooms / intermediate care unit; minimally invasive surgery, robotic-assisted laparoscopy, intraperitoneal chemotherapy, innovative anaesthesia procedures; endoscopy & interventional endoscopy.

• Radiotherapy: 6 accelerators : (1 x Cyberknife®- Accuray/ 1 x Tomotherapy®- Accuray / 2 x Rapid’Arc® /2 x Halcyon®-Varian) / 1 proton therapy unit : Proteus One®/ 1 x intraoperative radiotherapy (Intrabeam®) / Brachytherapy : High Dose Rate (HDR) Brachytherapy Source Projector.
• Radiology and Nuclear Medicine: PET-CT / 3 gamma cameras / MRI / CT scan / mammography / breast biopsy device / interventional radiology
• Biopathology department: Cytopathology and molecular diagnosis, NF S 96-900 certified Biobank / Next generation sequencing / Bio-informatic platform, molecular genetic platform / Oncogenetics. Medical biology laboratory and pathology department accredited to ISO 15189:2022 ISO 9001 certified Clinical Research Unit, and ISO 9001 certified Data Management

Education

The teaching mission at the Centre Baclesse is reflected in multiple ways: tutoring, internships, membership in a doctoral school, courses and bibliography sessions, continuing professional training, conferences and webinars within the institution and also many contributions in university teaching (pedagogical responsibility for modules, courses, practical work, tutorials, examination jury). These courses are provided by many health professionals who are keen to pass on their skills and the specificity of oncological care. Scientific training and events are also an important lever for creating a link with all the region's healthcare stakeholders involved in the patient's journey. The continuing education organisation of the Centre Baclesse is Qualiopi certified.

Presentation of the Centre

The Integrated Center for Oncology (ICO) - born in 2011 from the merge of the René Gauducheau Center in Nantes and Paul Papin Center in Angers - welcomes almost 45 000 patients per year thaks to 1300 employees, 200 physicians, 100 residents and 500 students. Specialised in oncology, ICO professionals support patients at every stage of their care pathway, through a personalised, innovating and multidisciplinary approach. Form quick diagnosis to surgery, chemotherapy and / or radiotherapy, ICO also offers patient support services, highly developed in our institution.

Main Research Activities

At ICO research is integrated into daily patient management.

Systemic medicine: Prevention (identifying predispositions to breast cancer in the population) - Personalization (giving the right patient the right treatment at the right time) and Safety (minimizing the toxicity of treatments)

Big data – machine learning: Modelling (integrating heterogeneous patient data to evaluate the cancer’s complexity), Innovation (developing new software tools to improve personalized cancer treatment), and Ethics (ethically managing databases in line with regulatory constraints).

Clinical research: Streamlined resources (using routine clinical data in clinical trials - Profitability (facilitating decision-making and improving the performances of phase III clinical trials) and Innovation (bringing the pharmaceutical industry virtual control arms).

Core Facilities

• Medical oncology – almost 40 000 chemotherapy sessions/year
• Radiotherapy – around 100 000 sessions / year, 11 accelerators and 1 intraoperative accelerator
• Medical imaging – 46 000 exams/year
• Nuclear medicine – more than 18 000 procedures/year
• Internal pharmacy
• Anatomical pathology laboratory
• Support services
• Surgery and Anaesthesia – 8 operating rooms and a monitoring unit, 5 600 surgery stays par year including 66% ambulatory stays

• Genomics
• Proteomics
• Transcriptomics
• Lipidomics
• Biological resource centre – Tumour Bank

Education

At ICO teaching and continuous professional training are a significant part of its mission. The majority of the staff of the cancerology section of the National University Advisory Board (Fr. Conseil National des Universités , CNU) of the Pays de la Loire Region are attached to ICO. Whilst all of the professional staff at the ICO contribute to the teaching mission, University-Hospital staff and University staff actively drive the training policy in the various disciplines present at the ICO.

Presentation of the Centre

The Centre Eugène Marquis - regional reference centre for cancer management of the Brittany region of France and member of UNICANCER network - was created in 1923, and was established as a regional cancer centre in 1945. It is an academic non-profit private institution that participates in the public health care system, in relation with Rennes’ University. Its missions involve patients’ care (including prevention), education and research, all focused on cancer.

The centre employs 585 health care professionals, dedicated to surgery (breast and skin only), radiotherapy (5 linac including 1 Cyberknife, an MRI-Linac and a brachytherapy unit), medical therapy (solid tumors), conventional (CT-scan and MRI) and interventional radiology, nuclear medicine (diagnostic and therapeutic), biology and supportive care. A total of 22 000 patients per year are treated in the institution (including 8 300 new patients/year).

Main Research Activities

At the Centre Eugène Marquis the research spreads from preclinical studies to clinical trials. Three domains are the core research activities of the center: breast tumors, hepato-biliary tumors, and image-guided radiotherapy. In these domains, prospective multicentric trials coordinated by the centre led to improvement in patient care. Emerging domains are the development of data science, cancer prevention, ethics and early phases trials, focusing on immunotherapy.

Core Facilities

The Centre Eugène Marquis provides facilities for all types of cancer treatments (surgery, radiotherapy, chemotherapy, interventional radiology, and nuclear medicine), as well as imaging modalities, and includes both in-patient and ambulatory care (medical,brachytherapy and surgical). A department of supportive and palliative care delivers medical and non-medical supportive interventions. The Centre hosts 3 Inserm research units (focused in cancer biology and image/big data processing), closely linked to the clinical research department (including a dedicated research ward with early phase accreditation) certified ISO 9001.

Education

The Centre Eugène Marquis is an academic centre, with a convention with the Rennes 1 university to provide education to medical students, at regional as well as national and international level. The institution includes several faculty members belonging to the different departments and provides teaching to nurses and other health professionals.

Institute’s presentation:

Professor Oscar Lambret found one of the first cancer department in the Saint-Sauveur Hospital in 1930 in Lille and the Oscar Lambret Center was found twenty five years later in 1955. It is a nonprofit institution collaborating with the different actors such as the French public healthcare system and especially the Lille University hospital Center. It is fully dedicated to oncology including the following practices: chemotherapy, radiotherapy, brachytherapy, supportive care and surgery.

Main Research Activities:

Clinical research is provided by the DRCI (Research and innovation direction) which coordinates clinical trials since 2016. Clinical research policy of Oscar Lambret Center is to give access to the patients to therapeutic innovations and contribute to clinical research developed under the consortium ONCOLille. DCRI has been certified ISO9001 : 2015. This international standard for quality attests the high degree of professionalism, the proper organisation and expertise of our team. In collaboration with the Lille university hospital and Alliance Cancer, DRCI was accredited by the INca and thus obtained the CLIP quality labeling in 2014 permitting the center to conduct early phase clinical trials in adults and children (first in man). The CLIP labelling has been reobtained by the DRCI in 2019 (until 2024), which recognizes our expertise in clinical research in oncology both in adults and children.

Core Facilities

• 9 radiotherapy (latest generation equipments)
• 2 gamma cameras
• 1 PET scan
• 1 3T.MRI and 1 1,5T.MRI
• 2 CT-scans
• 227 beds and places
  • 144 beds: 82 in medicine, 44 in surgery, 10 in intensive care unit, 8 radio protected rooms
  • 83 places: 40 for chemotherapy; 11 for ambulatory surgery; 8 for paediatric ambulatory: 5 for C2S; 14 for DRCI; 1 for nuclear medicine; 4 for venous access and endoscopic exploration unit
• 7 operating theatres

Education

The Oscar Lambret center plays an active role in the training of future professionals carrying out its teaching and research mission. It offers them a wide range of undergraduate and post-graduate education to train the specialists of tomorrow.

The Oscar Lambret training institute (IFOL) permits professionals in the region and beyond to benefit from a proper professional training. More than one throusand people every day are present in the center to be trained.

Description of the Centre

The Bergonié Institute (IB) is the Comprehensive Cancer Center (CCC) of the Nouvelle-Aquitaine region, one of the 19 french CCC which belong to UNICANCER network. Together with our partner Bordeaux University Hospital Centre (CHU), we are the regional reference center for oncology in Nouvelle-Aquitaine. IB is a non-profit private hospital dedicated to public service which contributes to medical progress and international influence of research in the prevention, detection and treatment of cancer.

Main Research Activities

The research of IB is structured around labeled structures that it hosts or with which it is associated. These structures cover the main areas of research in oncology, basic, technological, clinical, translational research, in epidemiology and public health and in human and social sciences. The offer of early access to new targeted molecules for patients (early phase trials within the framework of the Labeled Center INCa of Early Phases (CLIPP)) is a major focus for the Institute.

Core Facilities

More than a thousand employees, including more than a hundred physicians, ensure various missions such as patient care, research and oncology education. On a single site, the IB offers dedicated inpatient and outpatient cancer treatment including radiotherapy and chemotherapy as well as a number of related support services.

Education

All the medical, paramedical, administrative and logistical sectors of the Institute participate in training actions oriented around oncology. In initial training, the Institute welcomes nursing students, caregivers and electroradiology technicians. The Institute also offers a continuing education program including supportive oncological care, technical care and specific oncology treatments.

Presentation of the Institute and history

The Cancer Institute AP-HP. Nord – Université Paris Cité is a joint venture between 7 University hospitals of Université Paris Cité, all located in the north of Great Paris area: Saint-Louis, Bichat, Beaujon, Robert-Debré, Lariboisière, Louis-Mourier and Bretonneau. They gathered their forces in all oncology fields, developing reference activities in bone marrow transplantation, cell-therapies (CAR-T) and early phase clinical trials, to provide high-level cancer care and research, as a heritage of Nobel Prize winner Prof. Jean Dausset, the discoverer of the Major Histocompatibility Complex.

Main Research Activities

The Cancer Institute AP-HP. Nord – Université Paris Cité gathers 13 basic research teams and 25 clinical teams participating to a rich translational and basic science research activity in oncology, dedicated to hematological malignancies, cell therapy (Saint-Louis Research Institute), and solid cancers (Research Center on Inflammation), with the rise of targeted therapies and immunotherapy, based on the use of genomics biomarkers, cell biology platforms, bio-banking, and innovative imaging techniques. Moreover, our research activity builds on the strengths of the recently granted SIRIC InsiTu, SIRIC Paris Kids Cancer and IHU THEMA-2.

Core facilities

The Cancer Institute AP-HP. Nord – Université Paris Cité relies on outstanding facilities including 94 operating rooms - including 5 surgical ambulatory rooms, 2 PET- CT, 2 PET- SCAN, 1 PET-MRI, 11 MRI, 8 gama-cameras of which 2 coupled with CT-scan, 14 scanners, 7 bronchial and digestive endoscopy wards, 7 surgical robots. The radiotherapy department covers most of the modern radiotherapy techniques. The Meary cell-therapy Center at Saint-Louis Hospital is the most important facility in France for manufacturing CART-cells, while bone marrow transplantation activity is the greatest in Paris area, and beyond, in France.

Education

The Medicine Education and Research Unit, Faculty of Health of Université Paris Cité makes transformation and educational innovation its priority at all stages of training. Several PhD programs in cancer are coordinated by the Université Paris Cité hospitals and basic science research units.

Presentation of the Centre

Henri Becquerel Centre, attached to the French Federation of Centres for the Fight Against Cancer - UNICANCER Group, is an establishment of private law, non-profit and of public utility and participates in the public hospital service. It receives public funding and is subject to the supervision of the Regional Health Agency (ARS).

It falls into the category of health establishments Private Collective Interest (ESPIC).

In Normandy, the Henri Becquerel Center and the University Hospital of Rouen form the regional reference center for cancer and formed together a Health Cooperation Group (SCG): The Regional Cancer Institute of Haute-Normandie (IRCHN).

Main Activities

Like all Centres for the Fight Against Cancer, the Henri Becquerel Center provides a threefold mission:

• Care: screening, diagnosis, treatment and monitoring of cancer.
• Research: basic research, clinical research.
• Education: student training of medical and paramedical sectors.

Presentation of the Centre

The IUC, created in 2012, is the federative structure in charge of cancer research and medical activities within the AP-HP Hospital Group Sorbonne University and its seven hospitals* covering the eastern area of Paris, in relation with Sorbonne University and its 3 faculties of Health, Science and Engineering, and Arts in close collaboration with the Patients University, INSERM & CNRS research teams.

Key Figures

5,000 healthcare professionals, 90 care and research teams, 19,000 cancer patients every year (including almost 10,000 new cases).

* Pitié Salpêtrière, Saint-Antoine, Tenon, Charles Foix, Rothschild, Trousseau, La Roche Guyon

Main Research Activities

30 multidisciplinary clinical, translational and fundamental research teams in cooperation with the faculties of biology, engineering, science, mathematics, physics and human and social sciences.

Regarding clinical research, all the topics are covered in solid tumors and hematology, from pediatrics to oncogeriatrics, including prevention and human society within our 15 expert centers, and 10% of patients treated have been involved in a research program in prevention, diagnosis or treatment.

This expertise is recognized by more than a dozen NCI labels, as Integrated Cancer Research Site (SIRIC-CURAMUS), hospital-university federation (FHU S2C-HOPE), hospital-university health research program (RHU AI-TRIOMPH), labeled clinical research groups (GRC), Early Phase Center for adult & pediatric (CEPP), High Risk of Female Cancers Center, Primary CNS lymphomas (LOC), High Grade Oligodendrogliomas (POLA), rare cancer and cancer in immunodeficient patients or viral induced, immunosuppressive therapies, ESGO certified Ovarian Cancers Center. Finally, in 2025, the creation of a training and research chair for prevention and reduction cancer risk (CHAIRE" ECHECS AUX CANCERS").

Core Facilities

6 hospitals are offering close to 600 hospital beds dedicated to cancer patients.

All modern tools and platforms for prevention, diagnosis, treatment and patient follow-up, such as molecular Biology, Imaging, Pharmacological, NGS platform, Radiotherapy, Surgical robot, Pet IRM…

Cancer risk management platform, 5 accredited clinical research groups (GRC), Biology and investigation clinical research (CIB, CRB, CIC, CRC...), social facilities, Patient university and an active and engaged patient committee.

Education

The education as part of the faculty of medicine and the larger Sorbonne University structure on all topics of cancer for all types of professionals: physicians, nurses, and new professions.

The IUC specifically developed to inform and graduate patients, paramedical and medical professionals : cancer expert and partner patients with “Université des Patients”, specialized oncology nurses, interdisciplinary PhD program, international educational partnerships with Sao Paulo University Cancer Institute (Brazil), the Institute of Oncology and Radiotherapy (Belgrade, Serbia), Institute for Oncology and Radiotherapy (Belgrade, Serbia) and also as a member of the European university alliance 4EU+.

Presentation of the Centre

Institut Universitaire du Cancer Toulouse – Oncopole combines a centenary affiliated cancer centers in France, Oncopole Claudius Regaud, and Toulouse University Hospital oncology teams. It is strategically and physically linked to CRCT (Toulouse Cancer Research Center). This Comprehensive Cancer Center treats cancer patients, develops basic, transfer and clinical research and provides teaching. Opened 10 years ago in 2014, IUCT-Oncopole is involved in 11 113 new cases of cancer each year management. 2 175 staff-members including  191 physicians and  147 researchers are devoted to therapeutic innovation. The proximity and the pooling of platforms foster the care/research continuum

Main research activities

The CRCT (INSERM, CNRS and University) integrates research programs in 4 different fields: Cell Signaling & DNA Damage Response, RNA & Cancer, Microenvironment & Metabolism, Onco-Immunology. Its purpose is to solve problems and making discoveries through basic science that can lead to the development of anticancer agents and treatments.

Core Facilities

The innovative techniques for diagnosis and treatment at the service of patients for a global management:

• Medical oncology : 105 beds & places, oncogenetic service, MDT meetings, supportive care (therapeutic educational program, palliative care…).
• Clinical Trials: INCa-certified early phase centre by the French Cancer Institute, certified ISO 9001:2015, conducting phase I trials (part of the leading 3 national centers).
• Surgery: 65 beds & places,7 operating rooms, 50% of outpatient care for senology ; telerobotic, local cryotherapy (urology), per operative radiotherapy...
• Hematology and Internal Medicine: 100 beds & places, 150 clinical trials in progress.
• Nuclear medicine & Imaging: 18 beds & places, PET Scan, MRI, gamma cameras, 3D imaging.
• Radiotherapy: 7 accelerators (including tomotherapy), innovative techniques.
• Resuscitation unit: 12 beds
• Anatomopathology: telepathology, liquid and solid tumors, 1 000 exams/week, 2 special rooms for analyzing surgery samples quickly.
• Pharmacy:  125 000 chemotherapies/year, radiopharmacy, certified ISO 9001:2015

Education

Major changes in the practice of oncology must be taken into account and anticipated in training and teaching. This center of convergence for all disciplines represents an ideal forum for initial and continued training across the entire oncology fields.

Presentation of the Centre

Antoine Lacassagne’s Center is one of 19 French Unicancer centres devoted to the cancer struggle providing care (surgery, radiotherapy and medical treatments) teaching/training and research with professors from the scientific faculty and research labs.

Lacassagne welcomes 6,000 new patients a year and treats all types of cancers.

The Centre is the non-profit private health institute on the French Riviera.

Main Research Activities and Core Facilities

There is the long background of Antoine Lacassagne’s Center through some innovations we are proud of:

Radiotherapy is the flagship of Lacassagne, equipped with one of the most comprehensive platforms throughout Europe.

The sole Cyclotron built in a hospital with the first proton therapy treatment targeting choroidal melanomas in adults. Since 1991 6,500 patients have been treated, ie, about 5 % of patients worldwide.

The first cyberknife device in France in 2006.

The « Proteus One », the first high energy proton therapy device throughout the world. Treating 200 paediatric cancers a year.

The “Papillon 50” for contact therapy procedure.

In 2011 the “Head and Neck Institute” was set up gathering the teaching hospital and Lacassagne Center’s strengths.

It is a real organizational breakthrough as far as E.N.T. cancers are concerned.

In 2017 “Breast and Gynaecological Clinic” opened with its health care pathway with a modern technical platform gathering all the caregivers in a single location.

From the clinical research centre Phase I (16 th CLIPP in France) to our “Mozart institute”: a comprehensive supportive care and therapeutic education workshop integrated centre.

We are getting familiar with the patients’ healthcare pathway described by OECI A&D.

Since 2023, Lacassagne has met the highest standards of quality and risk management, granted by the French Health Authority.

Presentation of the Centre

Founded in 1740 by the Jansenist monk Jean Godinot such as a hospital for “cancered” patients, the Institut Godinot was the first cancer center in the world. Member of the UNICANCER network, the current Institute is an institution exclusively dedicated to oncology, with a Department of Surgery-Anesthesia, a Department of Radiotherapy and a Department of Medical Oncology. In addition, the Department of Imagery and Nuclear Medicine, the Pharmacy Department and the Department of Onco-biology, together with the Support Care Department, ensure the multidisciplinary and comprehensive care of patients.

The quality of care provided has been recognized by the certification of the French Haute Autorité de Santé at level “high quality of care”, namely the highest level of quality.

Main Research Activities

Research is divided into:

• Clinical research, with 10% of patients included in clinical trials; moreover, the Institute's Clinical Research Department was ISO 9001 certified in 2017. Clinical research is organized in collaboration with the local university hospital.
• Academic research, closely linked with the University of Reims.
• Epidemiologic research, conducted through a thyroid cancer registry, qualified at a national level since 2000.

Institut Godinot has also a certified and labelled Biological Resource Centre, including tumor and serum libraries.

Core Facilities

Godinot Institute’s infrastructures and equipment allow patients to access innovative diagnostic and treatment techniques:

• 114 beds and places
• 4 operating rooms
• Medical oncology: almost 17,000 chemotherapy sessions / year
• Radiotherapy: 5 accelerators – around 32,000 sessions / year
• Nuclear medicine: 3 gamma cameras, 2 PET scan – more than 13,500 procedures / year
• Medical imaging: 2 mammography, 1 MRI, 1 scanner – 21,500 exams / year
• Anatomical pathology laboratory
• ISO certified biobank
• ISO certified clinical research unit

Education

Godinot Institute plays a full role within the Faculty of Medicine of Reims and is the reference institution for training in oncology in our territory at two levels: graduate and post-graduate medical education and training.

The Institute's university staff are responsible for initial training in cancerology for medical students (all specialities), specific training for practitioners specialising in oncology, radiotherapy and nuclear medicine, and paramedical training in cancerology. The institute supervises interns and residents in medicine and pharmacy cursus.

Post-graduate educational programs are additionally developed by the institute, destined to liberal practitioners (pharmacists, general practitioners, nurses, …).

Presentation of the Centre

Centre Georges-François Leclerc (CGFL), a cancer care and research center at the forefront of innovation and dedicated to patients founded in 1967, is the only health facility exclusively dedicated to oncology for the Burgundy Franche-Comté region. The CGFL is a member of UNICANCER, which gathers the 18 French Cancer Centers.

Each year, the CGFL provides to 23,000 patients and their families a personalized medicine without excess to be paid and it has all the services and equipment for screening, diagnosis, outpatient treatment or hospitalization and its alternatives (day care, home care).

Main Research Activities

The CGFL develops a voluntarist policy of support for research activities basic, transfer and clinical research. It has a Clinical Research Center labeled by the Ministry of Health and is the only facility in the Grand Est of France to have an early phase research unit labeled CLIP² by the National Cancer Institute (INCa).

The research activities of the institution are organized around three structuring axes concerning personalized medicine in oncology (immunology, genomics, early phases), functional and molecular imaging, radiotherapy and radiobiology.

Core Facilities

6 operating rooms,

2 PET Scans including a total body PET 3 gamma cameras,

5 radiotherapy accelerators (including one coupled to an MRI), 1 Intrabeam® irradiation system dedicated to intraoperative radiotherapy,

1 MRI, 2 scanners, 1 mammotome, 2 mammographs,

6 NGS gene sequencers including 1 high-speed (and a third being acquired), 1 cell search cell sorter,

1 preclinical multimodal imaging platform (Spect, PET scan, PET-MRI, optical imager).

Education

Associate member of the “Université Bourgogne Europe” the CGFL contributes actively to the university and postgraduate education of doctors and specialists in the disciplines involved in oncology, as well as to paramedical professional training.

Presentation of the Centre

The Institut de Cancérologie de Lorraine, the first dedicated cancer treatment centre in Nancy, was created in 1924 with the acquisition of a Radium source in a surgical department. A group of pathologists, radiologists and surgeons was created then developed and became one of the French Regional Cancer Center in 1946. In 1976, a new hospital was built exclusively dedicated to cancer care which now includes 99 beds and 56 places and technical platforms on a surface of 30 000 square meters. The Institut de Cancérologie de Lorraine is a French Comprehensive Cancer Centre (FCCC), a non-profit health care institution, member of the UNICANCER Group. It houses all the human and technological means involved in the treatment, education and research in oncology.

Main Research Activities

Research is focused on clinical research, from phase I to III academic and industrial trials with 1120 studies producing 100 publications in 2023. Breast and digestive (colorectal and pancreatic) international publications are produced. for diagnostic and adaptation of the treatments. Translational research is developed by the Unit of Tumor Biology innovations with a special focus on liquid biopsies wich can improve diagnosis and treatments

Core Facilities

All techniques of diagnosis and treatment are available:

• The department of Radiotherapy is equipped with 6 linacs (35.000 fractions) including a Cyberknife and HDR-BT ans prostate seed implant facilities
• The department of Medical oncology delivers 25.000 cancer treatments, accompagned by a supportive care unit.
• The department of Surgery ( all except children and neurology) treats 3500 patients and has access
• Pathology, molecular biology, oncogenetic
• Imaging (except nuclear medicine in convention with university hospital)…

Education

Initial education is performed by professors, physicians and nurses, in medicine school, nurses schools and technicians of radiology. An e-learning school is developed as well as the participation to the virtual hospital program of the regional university of Lorraine. Over all, more then 4000 hours are dedicated for teaching courses.

Presentation of the Centre

GHU Paris-Saclay is one of the largest university hospital groups in the Paris region, and among the most renowned in France (ranked 13th in the 2025 Academic Ranking of World Universities, Shanghai). It is also a major reference center in oncology.

It brings together six hospitals: Paul-Brousse, Bicêtre, Antoine-Béclère, Ambroise-Paré, Raymond-Poincaré and Sainte-Périne, covering a wide range of medical and surgical specialties.

This network offers patients comprehensive and multidisciplinary cancer care pathways, from prevention and diagnosis to advanced treatments and supportive care.

Oncology activities are organized across several specialties, including digestive (colorectal, hepatobiliary and pancreatic cancers), thoracic, dermatology, gynecology and breast cancers, urology, hematology and pediatric oncology.

Dedicated multidisciplinary meetings and tumor boards ensure personalized management, integrating medical oncology, surgery, endoscopy, interventional procedures, as well as supportive care such as pain management and palliative medicine.

Research Activities and Education

Research is a cornerstone of GHU Paris-Saclay, conducted in close partnership with Inserm and Paris-Saclay University.

Teams participate in numerous national and international clinical trials and translational research programs.

Molecular biology and biobanking platforms for somatic and germline genetic analyses foster innovation, while hepatology, hepatobiliary surgery and digestive oncology are recognized as fields of excellence.

As a university hospital group, GHU Paris-Saclay is strongly committed to education, training medical students, residents, nurses and other healthcare professionals.

Presentation of the Institute

The Henri-Mondor University Cancer Institute (IUC) is the cancer center of the Henri-Mondor University Hospital Group (GHU), part of the Assistance Publique-Hôpitaux de Paris (AP-HP). It was created in partnership with the University of Paris-Est Créteil (UPEC) to coordinate cancer-related activities within the GHU. The IUC comprises two hospitals southeast of Paris.

Main Research Activities

The IUC translational and fundamental research is supported by the Mondor Institute for Biomedical Research (IMRB), Inserm-UPEC research unit, with 8 research teams active in the field of oncology. The IUC operates an early-phase center providing patients access to innovative treatments. Supported by the Clinical Research Unit and the Clinical Investigation Center, this clinical research enables patients to be enrolled in academic and industry-sponsored trials, across all disease stages.

Core Facilities

The IUC relies on a comprehensive range of medical and technical services with imaging (5 MRIs, 4 scanners), nuclear medicine, vectorized internal radiation therapy and laboratories with a genomic sequencing platform (2 HT sequencers). The IUC is also composed of a chemotherapy production unit with expertise in the field of reconstitution of IMP, and facilities for surgical treatment (21 operating rooms, 2 surgical robots), interventional radiology (3 rooms), endoscopy (3 rooms) and a department of radiation oncology (with 3 particle accelerators (1 with on-board MRI), 1 photobiomodulation device), among others. The IUC has facilities for supportive care with a dedicated platform, a readaptation unit and a Pain and Palliative Care Unit.

Education

The IUC professionals, in collaboration with UPEC, participate in training healthcare students, physicians, pharmacists, nurses and other caregivers. The IUC develops continuing education programs for professionals involved in cancer care and promotes interdisciplinary collaboration and knowledge sharing.

Presentation of the Centre

Institut public de Cancérologie Strauss Europe (Institut Strauss) is a non-profit Cancer Centre (CLCC) founded in 1923.

It is a member of Unicancer (a group that brings together all cancer centres in France) and the National Federation of Cancer Centres. This group brings together 20 French hospitals dedicated to cancer patients.

Cancer centres were created by an order dated 1 October 1945, supplemented by an order dated 2 May 2005.

These establishments have the status of legal entities under private law and are recognised as being of public utility (ESPIC: private healthcare establishment of collective interest).

A major player in public cancer care in Alsace, France and internationally, Institut Strauss brings together more than 600 doctors, caregivers and researchers specialising in oncology around its four missions: care, research and innovation, knowledge transfer and prevention.

Institut Strauss offers comprehensive cancer care, combining treatment, research and teaching at every stage of the process:

• Prevention, information and guidance for the public
• Early diagnosis and comprehensive, personalised care
• Appropriate and evaluated treatment
• Post-treatment integrated into care

Presentation of the Centre

Founded by the Doctor G. Reboul in 1946, the Institut Sainte Catherine is a no-profit hospital specialised in early diagnosis and medical cancer treatment, focused on care, teaching, clinical research and prevention. We are one of the 5 largest radiotherapy center in France with 56,000 radiotherapy sessions, 16,000 chemotherapy courses, 20,000 patients and 3,000 new patients, per year.

Main Research Activities

The Institute is certificated ISO 9001 since 2018 for its clinical trial investigation activity, and involves one dedicated physician, 2 senior clinical research coordinators end 11 clinical research associates. More than 2,600 patients are currently being monitored in clinical trials with 300 new patients every year.

Core Facilities

4 Hospitalisation Units:

• 66 beds for conventional hospitalisation, 22 beds for week hospitalisation, 52 beds for outpatient hospitalisation with 4 beds for clinical research and 6 beds for care support.

A Radiotherapy Platform:

• 7 Varian linear accelerators with onboard imaging, 2 “Novalis Truebeam”, 2 Halcyons
• 1 simuloscanner, 1 MR with simulation assignments 1 link with the PET, a Dosimetry with 14 treatment planning systems, 1 Brachytherapy equipement.

A Medical Imaging Technology Platform:

• 1 diagnostic CT-scan, 1 MR, 3 digital mammograms with angiomammography and tomosynthesis equipment.

Education

The Institute is involved in national, and international scientific societies (SFRO, SFPO, SFPM, ESTRO…) as in the Organisation of national trainings with VARIAN, MERCK and scientific meetings.

Presentation of the Institute

The Paris Seine-Saint-Denis Cancer Institute (ICaPSS) is the AP-HP’s cancer institute serving the population of Seine-Saint-Denis (93), a densely populated and culturally diverse territory located northeast of Paris, as well as neighboring departments such as Val-d’Oise and Seine-et-Marne.

It brings together the oncology care, research and education teams and technical platforms of AP-HP Paris Seine-Saint-Denis University Hospitals and Sorbonne Paris Nord University - the only medical university facilities in this region - across three hospitals: Avicenne (Bobigny), Jean-Verdier (Bondy) and René-Muret (Sevran).

Its ambition is to become a Comprehensive Cancer Centre, combining excellence in care, research and education accordance with the highest international standards, while remaining as close as possible to patients and their families.

Core Facilities

At ICaPSS, patients are our top priorities. Our integrated, multidisciplinary approach to solid-tissue cancers and haematological malignancies aims to make every care pathway coordinated, seamless and personalized, while ensuring access to therapeutic innovations.

The Martine Midy Supportive Care Space plays a key role, by providing supportive care alongside oncological treatments and by supporting patients and their relatives throughout their care journey. Patients are also active partners, with a focus on their experience, ethics and participation.

Main Research Activities

Fundamental, translational and clinical research come together at ICaPSS to accelerate the transfer of discoveries into clinical practice.

Supported by accredited academic research units, federated research structures and oncology technical platforms, our teams foster academic and industrial partnerships and facilitate access to early-phase clinical trials and innovative therapies.

Education

Under the academic leadership of Sorbonne Paris Nord University, ICaPSS supports medical, allied health and scientific training from undergraduate to doctoral levels, and develops international partnerships, notably with European Cancer Centres.

Presentation of the Centre

AP-HM is the University Hospital of Marseille, the second-largest city in France. It comprises 4 sites : North, Timone, Conception and South, with 3,400 beds, 130,000 admissions and 830,000 consultations a year.

AP-HM provides comprehensive care across multiple medical and surgical specialties, with a leading expertise in adult and pediatric oncology. Each year, AP-HM provides cancer care to more than 15,000 patients with approximately 100,000 oncology-related hospital stays.

Its Cancer Federation provides cross-site coordination across 10 adult specialties (gynecology, thoracic, neurology, urology, dermatology, hematology, head and neck, digestive, endocrine and sarcoma), and a pediatric one, with expertises as cancer referral site.

It has certification as cancer center of excellence at European (EURACAN since 2021), or national (Netsarc, Refcor, RREPS) levels.

Main Research Activities

AP-HM is strongly committed to research and innovation and, in partnership with Aix-Marseille University, is recognized as France's third-largest medical research center. It currently leads 2,100 research programs and 350 active oncology clinical trials. Since 2015, its research strategy has been strenghtened by INCA accredited center dedicated to early phase (CLIP²) in adult and pediatric cancers. AP-HM produces over 470 peer-reviewed publications annually.

Core Facilities

Its state-of-the-art technical platform enables comprehensive diagnostic and interventional care, including advanced imaging (PET and MRI), nuclear medicine, radiotherapy and interventional procedures, supported by high-level equipments such as Da Vinci robots, ROSA robots, and Gamma Knife.

Education

AP-HM also provides training for healthcare professionals in collaboration with Aix-Marseille University. AP-HM trains 3,600 students/year, including 1,630 interns.

Presentation of the Institution

Unicancer is the French Federation of Comprehensive Cancer Centres and the only hospital network in France entirely dedicated to cancer care. It brings together 18 Comprehensive Cancer Centres and 2 affiliated members across 22 hospital sites, representing more than 26 000 professionals committed to the care of over 600 000 patients every year.

The Comprehensive Cancer Centres are private, not-for-profit healthcare institutions carrying out a public-service mission. They provide comprehensive and multidisciplinary cancer care, covering prevention, diagnosis, treatment, supportive care, research and education. Their model combines high-level expertise, innovation and close integration between care and research, with the objective of giving every patient rapid access to the most appropriate treatments and technologies.

Research is a core mission of Unicancer and its network. Unicancer is a major academic player in oncology and the leading academic sponsor of oncology clinical trials in Europe, with more than 700 active clinical trials promoted across the network. Its activities span clinical and translational research, precision medicine and health-data research, with a strong focus on improving patient outcomes and accelerating access to innovation.

As a national federation, Unicancer also represents the Comprehensive Cancer Centres, supports cooperation and shared initiatives across the network, and develops partnerships with public authorities, academic institutions, patient organisations and international cancer networks. Through its national and European activities, Unicancer contributes to advancing cancer care, research and innovation and to promoting more equitable access to high-quality oncology services.